Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew to go before FDA panel

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic & Rehabilitation Devices Panel will review the firm's PMA application for its Birmingham Hip Resurfacing product Sept. 8 in Gaithersburg, Md. The cemented femoral component and uncemented acetabular component preserve the femoral head, unlike conventional hip surgery. Product is tailored to younger, more active patients, according to the firm (1"The Gray Sheet" March 15, 2004, p. 22). The panel will meet on Sept. 9 to discuss clinical trial designs for spinal devices for treating mild-to-moderate low back pain...

You may also be interested in...



New Hip Replacement Reflects Well On Smith & Nephew Sales Team – CEO

Smith & Nephew says the launch of its Reflection hip replacement implant in January has given its sales personnel increased standing with doctors to market the firm's full suite of hip products

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

The Aspirin Test For AI?

US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel